Coronary Artery Disease and Aspirin Intolerance: Background and Insights on Current Management

[1]  D. Atar,et al.  Why Not Dipyridamole: a Review of Current Guidelines and Re-evaluation of Utility in the Modern Era , 2021, Cardiovascular Drugs and Therapy.

[2]  T. Ulus,et al.  How to manage aspirin hypersensitivity in a patient with ST-segment elevation myocardial infarction and a drug-eluting stent. , 2021, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[3]  R. Caterina,et al.  Aspirin for primary prevention of cardiovascular disease: Advice for a decisional strategy based on risk stratification , 2019, Anatolian journal of cardiology.

[4]  J. Sheikh,et al.  Higher-starting-dose protocols in patients with coronary artery disease and aspirin hypersensitivity , 2019, Annals of Allergy, Asthma & Immunology.

[5]  A. Khera,et al.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[6]  R. Hajar.  Risk Factors for Coronary Artery Disease: Historical Perspectives , 2017, Heart views : the official journal of the Gulf Heart Association.

[7]  T. Laidlaw,et al.  Current Knowledge and Management of Hypersensitivity to Aspirin and NSAIDs. , 2017, The journal of allergy and clinical immunology. In practice.

[8]  P. Gurbel,et al.  Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary Artery Disease. , 2017, Circulation. Cardiovascular interventions.

[9]  H. Suryapranata,et al.  Acetylsalicylic acid desensitization in patients with coronary artery disease: A comprehensive overview of currently available protocols. , 2016, Vascular pharmacology.

[10]  Andrew A. White,et al.  Rapid Aspirin Challenge in Patients with Aspirin Allergy and Acute Coronary Syndromes , 2016, Current Allergy and Asthma Reports.

[11]  Linda A. Lindsay.  Type I Hypersensitivity Reaction , 2015 .

[12]  S. Rezkalla,et al.  The Role of Aspirin in the Prevention of Cardiovascular Disease , 2014, Clinical Medicine & Research.

[13]  K. L. McMullan.  Aspirin allergy in patients with myocardial infarction: the allergist's role. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[14]  M. Kowalski,et al.  Classification of reactions to nonsteroidal antiinflammatory drugs. , 2013, Immunology and allergy clinics of North America.

[15]  C. Gaudio,et al.  Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention , 2013, Platelets.

[16]  Andrew A. White,et al.  Characterization of aspirin allergies in patients with coronary artery disease. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[17]  P. Lieberman,et al.  Aspirin sensitivity and coronary artery disease: implications for the practicing cardiologist. , 2012, Future cardiology.

[18]  S. Leslie,et al.  Aspirin hypersensitivity and desensitization protocols: implications for cardiac patients , 2011, Therapeutic advances in drug safety.

[19]  Russ B Altman,et al.  Platelet aggregation pathway. , 2011, Pharmacogenetics and genomics.

[20]  M. Egger,et al.  Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis , 2011, BMJ : British Medical Journal.

[21]  A. Gavazzi,et al.  Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation. , 2008, The American journal of cardiology.

[22]  R. Simon,et al.  Selection of patients for aspirin desensitization treatment. , 2006, The Journal of allergy and clinical immunology.

[23]  P. Steg,et al.  Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. , 2005, The American journal of cardiology.

[24]  Raghava R. Gollapudi,et al.  Aspirin sensitivity: implications for patients with coronary artery disease. , 2004, JAMA.

[25]  V. Kalaria,et al.  Approach to “Aspirin Allergy” in Cardiovascular Patients , 2004, Circulation.

[26]  C. Jenkins,et al.  Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice , 2004, BMJ : British Medical Journal.

[27]  R. Flower.  What are all the things that aspirin does? , 2003, BMJ : British Medical Journal.

[28]  J. Vane,et al.  The mechanism of action of aspirin. , 2003, Thrombosis research.

[29]  M. Sánchez-Borges,et al.  Cutaneous reactions to aspirin and nonsteroidal antiinflammatory drugs , 2003, Clinical reviews in allergy & immunology.

[30]  K. Bloch,et al.  Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. , 2000, The Journal of allergy and clinical immunology.

[31]  P. Brooks,et al.  Clinical Pharmacokinetics of the Salicylates , 1985, Clinical pharmacokinetics.

[32]  J. Sheikh,et al.  Higher Dose Starting Protocols In Coronary Artery Disease Patients With Aspirin Hypersensitivity. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[33]  R. Shephard.  Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis , 2011 .

[34]  O. Walusinski.  Historical perspectives. , 2010, Frontiers of neurology and neuroscience.

[35]  C. Patrono.  Antiplatelet strategies , 2004 .

[36]  M. Sánchez-Borges,et al.  Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity. , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.